Serum total acid phosphatase for monitoring the clinical course of giant cell tumors of bone--26 patients with 5 local recurrences.
BACKGROUND
Giant cell tumor of bone (GCT) is a bone-destroying tumor that sometimes recurs locally after treatment. A recent study showed increased levels of serum total acid phosphatase (TACP).


METHODS
We assessed TACP in the serum of 26 patients with primary GCT, and in 5 of them who developed a local recurrence.


RESULTS
We found a correlation between TACP level in serum and tumor size. TACP levels that were elevated preoperatively in patients with GCT became normalized after surgery, but increased in 3 of the 5 patients with local recurrence.


CONCLUSIONS
TACP could be used as a tumor marker for monitoring response to treatment of GCT.
Akahane
Tsutomu
T
Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Isobe
Ken'ichi
K
Shimizu
Tominaga
T
D000135:Acid Phosphatase / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000201:enzymology* / Q000601:surgery; D005260:Female; D018212:Giant Cell Tumor of Bone / Q000097:blood / Q000201:enzymology* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000201:enzymology*
D014408:Biomarkers, Tumor; D000135:Acid Phosphatase